- A further milestone for Fresenius Kabi’s Vision 2026 growth strategy as the company invests on the core growth vector “Broaden in Biopharma”
- The combination of both companies positions Fresenius Kabi for accelerated medium- and long-term growth building on a highly complementary product offering in one of the fastest-growing areas of healthcare
- Enables entry into high-growth biologics Contract Development and Manufacturing (“CDMO”) market and provides access to highly cost competitive biologics manufacturing capacities
Fresenius Kabi closed the majority stake acquisition of mAbxience Holding S.L. (“mAbxience”), a leading international biopharmaceutical company. The transaction was previously announced on March 31, 2022.
“It is an exciting day as we announce the closing of the acquisition of a majority stake in mAbxience,” said Michael Sen, CEO of Fresenius Kabi. “With this transaction, we are achieving a major milestone in our biopharmaceuticals profile and advance as a company in terms of biologics product offering, manufacturing capabilities and business model. Together with mAbxience, we have around ten products on the market and in development, placing us in the upper third of the industry. We position ourselves to capture an essential share of the fast-growing biopharmaceutical market and welcome highly dedicated experts to our Fresenius Kabi family.”
The acquisition significantly strengthens Fresenius Kabi’s footprint in the biopharmaceuticals space by broadening its biosimilars portfolio and by gaining access to the distinctive development and manufacturing capabilities of mAbxience. The company operates three state-of-the-art facilities for the production of biologic drug substance, which addresses a critical gap in the value chain of Fresenius Kabi. “Thus, the acquisition enables Fresenius Kabi to provide a highly cost competitive end-to-end integrated biopharmaceutical offering, which allows for further expansion in the high-growth CDMO market and realization of significant cost synergies with regard to its own biosimilars portfolio,” said Michael Schönhofen, COO of Fresenius Kabi.
The purchase price is a combination of c. €495 million upfront payment and further milestone payments, strictly tied to the achievement of commercial and development targets. The contractual provisions also include a put / call option scheme regarding the sellers’ and future co-owners’ remaining shares in mAbxience (45%).